Skip to main content
Year archive

MESOBLAST LTD — 2019 filings

All 117 regulatory filings released by MESOBLAST LTD (MESO) in 2019, sourced directly from the official regulator.

117 Filings
2019 Period
2019 filings (117)
Filing Released Lang
6-K
Regulatory Filings
2019-12-24 English
DMC Completes Final Review of Phase 3 Heart Failure Trial 2 pages 124.6KB
Regulatory Filings
2019-12-17 English
CHF P3 Trial Accrues Sufficient Primary Endpoint Events 2 pages 129.0KB
Capital/Financing Update
2019-12-16 English
CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct) 2 pages 129.4KB
Regulatory Filings
2019-12-16 English
6-K
Director's Dealing
2019-12-12 English
Change of Director's Interest Notice 2 pages 78.1KB
Director's Dealing
2019-12-04 English
Ceasing to be a substantial holder 6 pages 218.1KB
Major Shareholding Notification
2019-12-04 English
6-K
AGM Information
2019-11-29 English
6-K
Interim / Quarterly Report
2019-11-27 English
6-K
Regulatory Filings
2019-11-27 English
Presentation to 2019 Annual General Meeting 33 pages 1.7MB
AGM Information
2019-11-26 English
Mesoblast Chairman Message to 2019 AGM 3 pages 109.7KB
AGM Information
2019-11-26 English
Results of Meeting 2 pages 182.9KB
Declaration of Voting Results & Voting Rights Announcements
2019-11-26 English
First Quarter Financial Results on Form 6-K 91 pages 518.0KB
Interim / Quarterly Report Q1 2020
2019-11-25 English
First Quarter Results Presentation 33 pages 1.7MB
Interim / Quarterly Report Q1 2020
2019-11-25 English
MSB Provides Q1 Financial Results and Operational Highlights 7 pages 318.7KB
Interim / Quarterly Report Q1 2020
2019-11-25 English
6-K
Regulatory Filings
2019-11-07 English
6-K
Regulatory Filings
2019-11-01 English
Appendix 4C - quarterly 9 pages 220.1KB
Interim / Quarterly Report Q1 2020
2019-10-30 English
Appointment of Joint Company Secretary 1 page 96.0K
Board/Management Information
2019-10-28 English
Appendix 4G and Corporate Governance Statement 19 pages 255.3KB
Regulatory Filings
2019-10-28 English
Notice of General Meeting/Proxy Form 20 pages 318.1KB
AGM Information
2019-10-28 English
Annual Report to shareholders 231 pages 5.4MB
Annual Report FY 2019
2019-10-28 English
Change in substantial holding 6 pages 238.5KB
Major Shareholding Notification
2019-10-22 English
Change in substantial holding 6 pages 89.8KB
Major Shareholding Notification
2019-10-22 English
Ceasing to be a substantial holder 4 pages 44.2KB
Major Shareholding Notification
2019-10-22 English
6-K
Regulatory Filings
2019-10-22 English
MSB and Lonza Enter GVHD Commercial Manufacturing Agreement 3 pages 98.8KB
Capital/Financing Update
2019-10-16 English
6-K
Capital/Financing Update
2019-10-10 English
Change in substantial holding 4 pages 537.2KB
Major Shareholding Notification
2019-10-09 English
Change in substantial holding 4 pages 74.5KB
Major Shareholding Notification
2019-10-07 English
Cleansing notice and Appendix 3B 8 pages 151.2KB
Capital/Financing Update
2019-10-07 English
6-K
Regulatory Filings
2019-10-04 English
6-K
Regulatory Filings
2019-10-03 English
Mesoblast Raises A$75 Million 2 pages 116.9KB
Capital/Financing Update
2019-10-02 English
Trading Halt 2 pages 298.6KB
Capital/Financing Update
2019-09-30 English
Mesoblast Newsletter - Chronic Low Back Pain 3 pages 594.6KB
Investor Presentation
2019-09-26 English
Release of Shares from Voluntary Escrow 1 page 91.0
Regulatory Filings
2019-09-26 English
6-K
Investor Presentation
2019-09-11 English
Grunenthal and MSB Enter Strategic Partnership for Back Pain 4 pages 132.2KB
Regulatory Filings
2019-09-09 English
Analyst Call Details 1 page 87.1KB
Regulatory Filings
2019-09-09 English
Analyst Call Presentation 26 pages 1.8MB
Regulatory Filings
2019-09-09 English
20-F
Annual Report FY 2019
2019-09-09 English
6-K
Regulatory Filings
2019-09-06 English
6-K
Regulatory Filings
2019-08-30 English
Preliminary Final Report including Appendix 4E 232 pages 3.9MB
Annual Report FY 2019
2019-08-29 English
Annual Financial Results Presentation 48 pages 4.6MB
Regulatory Filings
2019-08-29 English
Mesoblast Reports on Annual Results 10 pages 250.3KB
Annual Report FY 2019
2019-08-29 English
FDA Guidance on Clinical Pathway for LVAD Market Application 3 pages 115.5KB
Regulatory Filings
2019-08-26 English
6-K
Regulatory Filings
2019-08-19 English
Investigator-Initiated Trial Planned for Chronic GVHD 2 pages 78.3KB
Regulatory Filings
2019-08-13 English
6-K
Regulatory Filings
2019-08-13 English
Mesoblast Appoints Leading Pharma Industry Executive as CMO 2 pages 76.8KB
Board/Management Information
2019-08-11 English
6-K
Regulatory Filings
2019-08-02 English
Appendix 4C - Quarterly, Strong Commercialization Revenues 9 pages 205.9KB
Interim / Quarterly Report FY 2019
2019-07-30 English
6-K
Regulatory Filings
2019-07-30 English
Circulation Research Highlights MSB Heart Failure Therapy 2 pages 131.1KB
Regulatory Filings
2019-07-24 English
6-K
Regulatory Filings
2019-07-17 English
Newsletter - Interview with GvHD Key Opinion Leader 3 pages 951.3KB
Regulatory Filings
2019-07-14 English
Change in substantial holding 4 pages 80.6KB
Major Shareholding Notification
2019-07-11 English
Appendix 3B 13 pages 118.9KB
Capital/Financing Update
2019-07-10 English
Release of Shares from Voluntary Escrow 1 page 90.6
Share Issue/Capital Change
2019-06-25 English
FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs 3 pages 143.6KB
Regulatory Filings
2019-06-23 English
6-K
Regulatory Filings
2019-06-19 English
High Economic Burden In Steroid-Refractory aGVHD 2 pages 101.3KB
Regulatory Filings
2019-06-17 English
MSB to Host Virtual Symposium with KOL on GvHD 2 pages 97.9KB
Investor Presentation
2019-06-16 English
6-K
Regulatory Filings
2019-06-12 English
MSB Expands JCR Partnership To Brain Disease In Newborns 2 pages 100.4KB
Capital/Financing Update
2019-06-10 English
6-K
Interim / Quarterly Report
2019-06-01 English
6-K
Regulatory Filings
2019-06-01 English
6-K
Regulatory Filings
2019-05-31 English
Third Quarter Financial Results on Form 6-K 99 pages 552.9KB
Interim / Quarterly Report 9M 2019
2019-05-30 English
Third Quarter Results Presentation 43 pages 3.5MB
Interim / Quarterly Report 9M 2019
2019-05-30 English
MSB Provides Q3 Financial Results and Operational Highlights 7 pages 189.2KB
Interim / Quarterly Report 9M 2019
2019-05-30 English
Mesoblast Initiates Rolling Submission of BLA for GvHD 2 pages 100.9KB
Capital/Financing Update
2019-05-29 English
MSB Financial Results Webcast Timing 1 page 73.9KB
Regulatory Filings
2019-05-29 English
6-K
Regulatory Filings
2019-05-29 English
Mesoblast Keynote Presentations at ISCT Annual Meeting 2 pages 253.8KB
Regulatory Filings
2019-05-22 English
6-K
Regulatory Filings
2019-05-21 English
Mesoblast to Present at RBC Global Healthcare Conference 1
Investor Presentation
2019-05-16 English
6-K
Regulatory Filings
2019-05-06 English
Appendix 4C - quarterly 6 pages 129.2KB
Interim / Quarterly Report Q3 2019
2019-04-29 English
6-K
Regulatory Filings
2019-04-23 English
FDA Agrees to Rolling Review of Mesoblast BLA Submission 2 pages 127.7KB
Capital/Financing Update
2019-04-15 English
6-K
Director's Dealing
2019-04-11 English
Presentation at Upcoming Global Life Science Conference 1
Investor Presentation
2019-04-04 English
Final Director's Interest Notice 2 pages 63.0KB
Director's Dealing
2019-04-04 English
6-K
Regulatory Filings
2019-03-28 English
MoU for Confirmatory Trial for GI Bleeding in LVAD Patients 2 pages 112.4KB
Regulatory Filings
2019-03-26 English
6-K
Regulatory Filings
2019-03-25 English
MSB Licensee Files For Skin Disease Marketing Approval 2 pages 96.4KB
Regulatory Filings
2019-03-24 English
Joseph R. Swedish Appointed Mesoblast Chairman 2 pages 94.9KB
Board/Management Information
2019-03-21 English
Change in substantial holding 6 pages 193.3KB
Major Shareholding Notification
2019-03-17 English
6-K
Regulatory Filings
2019-03-14 English
Upcoming U.S. Investor Conferences 1 page 100.2KB
Regulatory Filings
2019-03-12 English
6-K
Interim / Quarterly Report
2019-02-22 English
6-K
Investor Presentation
2019-02-22 English
6-K
Regulatory Filings
2019-02-21 English
Half Year Report and Accounts (including Appendix 4D) 105 pages 725.5KB
Interim / Quarterly Report H1 2019
2019-02-20 English
Half Year Financial Results Presentation 25 pages 1.4MB
Interim / Quarterly Report H1 2019
2019-02-20 English
Mesoblast Provides Half Year Results and Corporate Update 7 pages 191.8KB
Interim / Quarterly Report H1 2019
2019-02-20 English
Mesoblast Newsletter on Advanced and End-Stage Heart Failure 3 pages 246.7KB
Management Reports
2019-02-18 English
Final Patient Dosed in Mesoblast P3 Heart Failure Trial 2 pages 91.9KB
Regulatory Filings
2019-02-18 English
SC 13G
Major Shareholding Notification
2019-02-14 English
SC 13G/A
Major Shareholding Notification
2019-02-14 English
Change in substantial holding 6 pages 194.3KB
Major Shareholding Notification
2019-02-10 English
MESOBLAST LTD
Major Shareholding Notification
2019-02-05 English
6-K
Regulatory Filings
2019-02-05 English
Appendix 4C - quarterly 6 pages 127.8KB
Interim / Quarterly Report Q2 2019
2019-01-30 English
6-K
Regulatory Filings
2019-01-18 English
MSB Draws US$15 Million From Existing Facility 2 pages 128.9KB
Capital/Financing Update
2019-01-13 English
6-K
Director's Dealing
2019-01-12 English
Change of Director's Interest Notices 14 pages 188.6KB
Director's Dealing
2019-01-07 English
MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase 2 pages 220.6KB
Regulatory Filings
2019-01-07 English
Cleansing notice and Appendix 3B 13 pages 201.9KB
Share Issue/Capital Change
2019-01-06 English
P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment 2 pages 94.5KB
Capital/Financing Update
2019-01-06 English
6-K
Regulatory Filings
2019-01-04 English